Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study
EClinicalMedicine. 2024 Mar 20;71:102552. doi: 10.1016/j.eclinm.2024.102552. eCollection 2024 May.ABSTRACTBACKGROUND: Abemaciclib is currently approved for the adjuvant treatment of high-risk, lymph node (LN)-positive, hormone receptor (HR)-positive breast cancer (BC). In a real-world setting the clinicopathologic features of patients potentially eligible for adjuvant abemaciclib remain to be defined. There are conflicting data regarding the biological behavior and long-term outcomes across invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). In our study we retrospectively assessed the real-world data and long-term outcome of selected high-risk features ILC compared to IDC, according to the MonarchE trial inclusion criteria.METHODS: We identified 15,071 patients who got surgery at the European Institute of Oncology for a first primary, non-metastatic, HR-positive, HER2-negative BC from 2000 to 2008. 11,981 (79.5%) patients had an IDC and 1524 (10.1%) an ILC. The remaining 1566 patients (10.4%) had either combined ductal and lobular breast cancer or another histological breast cancer subtype. According to the eligibility criteria of the MonarchE study, we identified two high-risk groups, based on high number of positive lymph nodes, large tumor size, or a high cellular proliferation as measured by tumor grade or biomarkers. Patients were matched by propensity score.FINDINGS: A total of 2872 (21.3%) patients were selected as clinically high-risk, including 361...
Source: Cancer Control - Category: Cancer & Oncology Authors: Francesca Magnoni Giovanni Corso Patrick Maisonneuve Beatrice Bianchi Giuseppe Accardo Claudia Sangalli Giulia Massari Anna Rotili Luca Nicosia Filippo Pesapane Emilia Montagna Giovanni Mazzarol Viviana Galimberti Paolo Veronesi Giuseppe Curigliano Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Ductal Carcinoma | Funding | HER2 | Hormones | Lobular Carcinoma | Statistics | Study